2 Information about daratumumab
Marketing authorisation indication
2.1 Daratumumab (Darzalex, Janssen) in combination with lenalidomide and dexamethasone is indicated for 'the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant'.
Dosage in the marketing authorisation
2.2 The dosage schedule for both injection and infusion formulations are available in the summary of product characteristics for daratumumab.
Price
2.3 The list prices for daratumumab (excluding VAT; BNF online, accessed August 2023) are:
-
£4,320 per 1,800 mg/15 ml solution for injection vial
-
£360 per 100 mg/5 ml concentrate for solution for infusion vial
-
£1,440 per 400 mg/20 ml concentrate for solution for infusion vial.
2.4 The company has a commercial arrangement. This makes daratumumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.
2.5 The list price for lenalidomide is £3,057.60 per 21‑pack of 25‑mg capsules (excluding VAT; BNF online, accessed August 2023). List prices for different doses are available on the BNF webpage for medicinal forms of lenalidomide. There is a discount for lenalidomide agreed with the Commercial Medicines Unit. The prices agreed through the framework are commercial in confidence.
2.6 The list price of dexamethasone is £30.73 per 50‑pack of 4‑mg capsules (excluding VAT; electronic market information tool [eMIT] online, accessed August 2023). List prices for different doses are available on the BNF webpage for medicinal forms of dexamethasone. Costs may vary in different settings because of negotiated procurement discounts.